Switch theme
Sign up to access all valuation multiples
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
2009
305
Last FY Revenue $39.6M
Last FY EBITDA -$185M
-$182M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Bicycle Therapeutics achieved revenue of $39.6M and an EBITDA of -$185M.
Bicycle Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bicycle Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $39.6M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$185M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -467% | XXX | XXX | XXX |
| EBIT | XXX | -$235M | XXX | XXX | XXX |
| EBIT Margin | XXX | -593% | XXX | XXX | XXX |
| Net Profit | XXX | -$190M | XXX | XXX | XXX |
| Net Margin | XXX | -479% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bicycle Therapeutics's stock price is EUR 8 (or $9).
Bicycle Therapeutics has current market cap of EUR 536M (or $603M), and EV of -EUR 162M (or -$182M).
See Bicycle Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$182M | $603M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bicycle Therapeutics has market cap of $603M and EV of -$182M.
Bicycle Therapeutics's trades at -4.6x EV/Revenue multiple, and 1.0x EV/EBITDA.
Equity research analysts estimate Bicycle Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bicycle Therapeutics's P/E ratio is not available.
See valuation multiples for Bicycle Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $603M | XXX | $603M | XXX | XXX | XXX |
| EV (current) | -$182M | XXX | -$182M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBicycle Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Bicycle Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bicycle Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bicycle Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -467% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 490% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 693% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bicycle Therapeutics acquired XXX companies to date.
Last acquisition by Bicycle Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bicycle Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bicycle Therapeutics founded? | Bicycle Therapeutics was founded in 2009. |
| Where is Bicycle Therapeutics headquartered? | Bicycle Therapeutics is headquartered in Germany. |
| How many employees does Bicycle Therapeutics have? | As of today, Bicycle Therapeutics has 305 employees. |
| Who is the CEO of Bicycle Therapeutics? | Bicycle Therapeutics's CEO is Dr. Kevin Lee, M.B.A.,PhD. |
| Is Bicycle Therapeutics publicy listed? | Yes, Bicycle Therapeutics is a public company listed on BER. |
| What is the stock symbol of Bicycle Therapeutics? | Bicycle Therapeutics trades under 50BA ticker. |
| When did Bicycle Therapeutics go public? | Bicycle Therapeutics went public in 2019. |
| Who are competitors of Bicycle Therapeutics? | Similar companies to Bicycle Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Bicycle Therapeutics? | Bicycle Therapeutics's current market cap is $603M |
| Is Bicycle Therapeutics profitable? | Yes, Bicycle Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
